In 200 patients with recurrent glioblastoma, FET-PET-guided vs contrast-enhanced MRI-guided re-irradiation target delineation did not improve median PFS (4.0 vs 4.9 months; adjusted HR 1.14, p=0.39). Grade 3-4 radionecrosis was 8% vs 7%.
RCTn = 200
Grosu et al. O-(2-[18F]fluoroethyl)-L-tyrosine-PET-guided versus contrast-enhanced T1-weighted MRI-guided re-irradiation in patients with recurrent glioblastoma (GLIAA/NOA-10 ARO2013-01): a multicentre, open-label, randomised trial